Morrisville, PA, United States of America

David Brent Rawlins

This inventor holds 19 USPTO granted patents and 3 published patent applications, plus 4 CIPO patents and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Lexicon Pharmaceuticals, Inc., Bristol-Myers Squibb Compnay. Active years: 2000-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Brent Rawlins. Retrieved from https://idiyas.com/inventor/david-brent-rawlins

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 3)

% Patents Active = 89.5

CIPO Patents = 4

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 5.3

ph-index = 7

Forward Citations = 181(Granted Patents)

Location History:

Morrisville, NJ (US) (2015)
Morrisville, PA (US) (2000 - 2018)

Company Filing History:

11 out of 89

Lexicon Pharmaceuticals, Inc.

patents

8 out of 3,749

Bristol-Myers Squibb Compnay

patents

Years Active: 2000-2018

Loading Chart...

Areas of Expertise:

Sodium Glucose Transporter

LIM Kinase 2

Cyclin Dependent Kinases

Inhibitors

Pyrrolo Compounds

Piperdine

Aminothiazole

Dihydropyrimidine

Chemokine Receptor

Therapeutics

Substituted Compounds

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10106569 - Inhibitors of sodium glucose transporter 1 for constipation (2018-10-23),

2. 9688710 - Inhibitors of sodium glucose cotransporter 1 (2017-06-27),

3. 9365602 - Sodium glucose co-transporter inhibitors and methods of their use (2016-06-14),

4. 9200025 - Inhibitors of sodium glucose cotransporter 1 (2015-12-01),

5. 8507672 - Substituted pyrrolo[2,3-d]pyrimidines as LIM kinase 2 inhibitors (2013-08-13),

6. 8476413 - Sulfanyl-tetrahydropyran-based compounds and methods of their use (2013-07-02),

7. 8450332 - LIMK2 inhibitors, compositions comprising them, and methods of their use (2013-05-28),

8. 8193202 - LIMK2 inhibitors, compositions comprising them, and methods of their use (2012-06-05),

9. 7846945 - Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use (2010-12-07),

10. 7781577 - Inhibitors of sodium glucose co-transporter 2 and methods of their use (2010-08-24),

11. 7423043 - [object Object] (2008-09-09),

12. 6809102 - Cyano-substituted dihydropyrimidine compounds and their use to treat diseases (2004-10-26),

13. 6720347 - Carbon substituted aminothiazole inhibitors of cyclin dependent kinases (2004-04-13),

14. 6649606 - Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity (2003-11-18),

15. 6521759 - Aminothiazole inhibitors of cyclin dependent kinases (2003-02-18),

Title: David Brent Rawlins – Innovator in Pharmaceutical Technologies

Introduction

David Brent Rawlins, an accomplished inventor based in Morrisville, PA, is credited with 19 patents to his name. His contributions primarily focus on pharmaceutical innovations, particularly involving glucose transport and diabetes treatments. His work reflects a commitment to addressing critical health issues through inventive solutions.

Latest Patents

Among his latest patents are notable inventions related to inhibitors of sodium glucose transporter 1 (SGLT1). These patents encompass compositions designed to treat various diseases and disorders, including diabetes, through the modulation of SGLT1. The specific compounds he developed are defined precisely with various substituents, showcasing his meticulous approach to pharmaceutical formulation.

Career Highlights

Throughout his career, David Brent Rawlins has held significant roles in leading pharmaceutical companies, including Lexicon Pharmaceuticals, Inc. and Bristol-Myers Squibb Company. His tenure at these organizations has allowed him to influence drug development and advance therapies that improve patients' lives.

Collaborations

David has collaborated with notable individuals in the field, such as Bryce Alden Harrison and Ross Mabon. These partnerships have fostered a rich environment for innovation and creativity, resulting in numerous advancements in the pharmaceutical sector.

Conclusion

David Brent Rawlins stands out as a key figure in pharmaceutical innovation. His extensive portfolio of patents, focus on SGLT1 inhibitors, and collaborative spirit emphasize his dedication to enhancing medical treatments. As he continues to contribute to the field, his work promises to leave a lasting impact on healthcare and patient outcomes.

Profile summary based on public USPTO records.